Complete response of MSI-high metastatic colon cancer following treatment with regorafenib: A case report

Regorafenib has been demonstrated to prolong survival in patients with metastatic colorectal cancer refractory to standard chemotherapy. However, overall survival is limited to 2.5 months. The present report describes a unique case of metastatic colon cancer, which showed a complete response to rego...

Descripción completa

Detalles Bibliográficos
Autores principales: Baik, Hyungjoo, Lee, Hee Ju, Park, Jueun, Park, Ha Young, Park, Jinyoung, Lee, Sunseong, Bae, Ki Beom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506641/
https://www.ncbi.nlm.nih.gov/pubmed/34650810
http://dx.doi.org/10.3892/mco.2021.2405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506641/
https://www.ncbi.nlm.nih.gov/pubmed/34650810
http://dx.doi.org/10.3892/mco.2021.2405

Ejemplares similares